ATR and WEE1 Inhibitors After PARP Resistance: Emerging DNA Damage Response Strategies Across Solid Tumors Review Abstract Background Resistance to poly(ADP-ribose) polymerase (PARP) inhibition has intensified interest in other components of the DNA damage response and replication-stress network. Early clinical studies have evaluated ataxia telangiectasia
Tag: clinical trials
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
Top Medical News Topics Clinicians Should Know This Week
Top Medical News Topics Clinicians Should Know This Week Medical NEWS - See topic summary at the end Abstract Time window: June 15–21, 2026, inclusiveSelection logic: This roundup includes medical news items that were published, announced, updated, or otherwise had a clearly documented clinical, regulatory, public health,
BPC-157 and TB-500: Background, Indications, Efficacy, and Safety
BPC-157 and TB-500: Background, Indications, Efficacy, Safety, and the Role of Cancer Pre-Screening in Clinical Use Check back later for a possible video summary. Target Audience: This article is written for physicians, clinical researchers, and allied healthcare professionals seeking an advanced understanding
CBD and Seizures: New Clinical Evidence Challenges Common Beliefs
CBD and Seizures: New Clinical Evidence Challenges Common Beliefs Introduction CBD and seizures research has skyrocketed in recent years, challenging traditional treatment paradigms for refractory epilepsy. Epilepsy affects approximately 50 million people globally, according to the World Health Organization (WHO). This neurological disorder, previously limited
macular edema therapy using dexamethasone nanoparticle suspension
macular edema therapy using dexamethasone nanoparticle suspension PURPOSE To determine the effectiveness and safety of a new topical nanoparticle dexamethasone ophthalmic suspension OCS-01 (Oculis SA, Lausanne, Switzerland) in the treatment of diabetic macular edema (DME). STUDY BACKGROUND Diabetic macular edema (DME) is the main cause of visual impairment in patients with diabetic retinopathy (DR).
Meta-Analysis to Determine Optimal Therapy Strategies in Macular Degeneration
Meta-Analysis Results of Clinical Trial Aimed at Determining Optimal Therapeutic Strategies for anti-VEGF Therapy in nAMD Background of this Study Neovascular age-related macular degeneration (nAMD) affects as many as 196 million people worldwide, and is a major cause of severe vision problems including blindness. Despite its prevalence, disagreements about the treatment options
Tool for evaluating real world evidence in treatment of retinal disease
Tool for Evaluating RWE in the Treatment of Retinal Disease Randomized clinical trials have long been held as the gold standard for evidence based medical practices. However, there is a growing consciousness about the value of incorporating data from real world evidence (RWE) into clinical decision making. Information from real world sources such
